BEST OF ONCOLOGY WEST 2024: Non-Prostate GU Cancer – Dr. Maryam Soleimani

BEST OF ONCOLOGY WEST 2024: Non-Prostate GU Cancer – Dr. Maryam Soleimani

Best of Oncology West Conference 2024
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Dr. Daniel Heng

Icon Chair Speaker

Panelist

Dr. Maryam Soleimani

Studies/trials discussed:

  • Cosmic 313 Study
  • Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  • Lenvatinib plus pembrolizumab Study
  • Lenvatinib plus pembrolizumab in patients
  • Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
  • LBA88 Belzutifan versus everolimus in participants
  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
  • Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Studies/trials discussed:

  • Cosmic 313 Study
  • Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  • Lenvatinib plus pembrolizumab Study
  • Lenvatinib plus pembrolizumab in patients
  • Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
  • LBA88 Belzutifan versus everolimus in participants
  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
  • Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Tagged